NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced that the Brazilian Patent and Trademark Office has issued ...
Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes ...
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical ...
Detailed price information for Sab Biotherapeutics Inc (SABS-Q) from The Globe and Mail including charting and trades.
T1D Scout founder Yuta Matsuda explains how the swab-based, at-home genetic testing he developed works – and how it can help more families access type 1 diabetes screening. Type 1 diabetes screening ...
New data from ADA 2026 reveal that assumptions around age, weight, and gestational history are leaving too many T1D patients misclassified — and the clinical consequences are preventable. Our modern ...
Under the terms of MacroGenics’ agreement with Sanofi, the recent FDA approval triggered a $24.5 million regulatory milestone payable to MacroGenics. The Company remains eligible to receive up to $305 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results